While formal pharmacokinetic studies of GLP-1RA co-administration with these IBD drugs have not been conducted, clinicians should monitor for unexplained changes in therapeutic response, particularly during GLP-1RA initiation and dose escalation, and consider staggering oral medications when feasible
Back Schuler, J, Shearin, E (2005) 'Amylin and Lilly announce FDA approval of BYETTA(TM) (Exenatide) Injection', Lilly News Release
Neurol Sci
References: National Center for Biotechnology Information.
Retatrutide is Eli Lillys once-weekly injectable triple agonist (GLP-1, GIP, and glucagon receptors) still working through Phase 3 trials, with the headline TRIUMPH-4 readout showing roughly 28.7% body-weight reduction at the 12 mg dose over 68 weeks
Insurance companies need to determine coverage